We identified a potential five-biomarker panel (BPIFA1, MUC5AC, CAMP, CTSG, and ANXA1) that illustrates the inflammatory activity of asthma in sputum and could improve asthma phenotyping, providing valuable insights into personalized treatment approaches. This evidence concerns the gene ANXA1 and asthma.